Eliem Therapeutics is developing novel therapies for neuronal excitability disorders. Tens of millions of people suffer from central and peripheral nervous system disorders which are caused by imbalances in excitation and inhibition of neuronal networks. Eliem has created ETX-155, their lead candidate, to treat major depressive disorder and focal onset seizures. ETX-155 is an oral neuroactive steroid that activates GABA-A receptors resulting in a decrease in neuron excitability and firing. Eliem has tested ETX-155 in Phase 1 clinical trials and is now planning Phase 2. Eliem is also progressing a pipeline of preclinical candidates including targeting the Kv7.⅔ channel protein.

Eliem Therapeutics

Short description:

Drug notes:

Long description:

Jobs: